1 Min Read
Nov 16 (Reuters) - Medicenna Therapeutics Corp
* Medicenna presents updates on phase 2b clinical trial of MDNA55 at the annual meeting of the society of neuro-oncology Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.